2 Deaths Prompt FDA Probe Of Eli Lilly's Zyprexa Relprevv

Law360, New York (June 18, 2013, 1:25 PM EDT) -- The U.S. Food and Drug Administration on Tuesday said it has opened an investigation after two patients died following injections of Eli Lilly & Co.'s schizophrenia drug Zyprexa Relprevv, the latest bad news for a troubled product line.

Agency officials cautioned that the deaths were unexplained, but noted that the two patients were found to have "very high" levels of active ingredient olanzapine in their blood. High doses of the drug can cause delirium, disrupt heart rhythm, lead to cardiac arrest and result in lower levels...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.